Aytu Biopharma (AYTU) Share-based Compensation (2014 - 2026)

Aytu Biopharma (AYTU) has 13 years of Share-based Compensation data on file, last reported at $148000.0 in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $148000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (changed 0.36% YoY), and the FY2025 annual result was $576000.0, down 80.23% from the prior year.
• Share-based Compensation slipped to $148000.0 in Q1 2026 per AYTU's latest filing, from $283000.0 in the prior quarter.
• Over five years, Share-based Compensation peaked at $3.1 million in Q4 2022 and troughed at $114000.0 in Q3 2025.
• A 5-year average of $832687.5 and a median of $815500.0 in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2024: Share-based Compensation jumped 149.55% in 2022, then plunged 81.59% in 2024.
• A 5-year view of Share-based Compensation shows it stood at $3.1 million in 2022, then tumbled by 73.26% to $820000.0 in 2023, then sank by 81.59% to $151000.0 in 2024, then soared by 87.42% to $283000.0 in 2025, then slumped by 47.7% to $148000.0 in 2026.
• Business Quant data shows AYTU's Share-based Compensation at $148000.0 in Q1 2026, $283000.0 in Q4 2025, and $114000.0 in Q3 2025.